Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.

source https://finance.yahoo.com/news/glaxo-submits-first-regulatory-application-140702724.html?.tsrc=rss